This story explores how potential demand for rarer cannabinoids is prompting firms to explore other methods of manufacturing, such as biosynthesis and chemical synthesis, to give higher yields at lower cost.
These rarer cannabinoids are being trialled for potential therapeutic effects of a range of physical and mental conditions.
The story examines the development efforts of three North American companies in particular to research effects and to achieve economical production.
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Benefits of subscription plans:
Stay informed of any legal and market change in the sector that impacts your organization
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
Start your FREE trial
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.